Investment Considerations Proprietary R&D is led by a world-class team of medicinal chemists and industry veterans, ensuring innovative product development. A first-to-market product, unbuzzd addresses a fast-expanding consumer category, with 300% growth expected by 2030. Lucid-MS, a potential multi-billion-dollar asset, represents a significant breakthrough in the treatment of demyelinating diseases, supported by an expedited regulatory … Continue reading “Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)”
Symbol | Release | Time |
---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |